glp-1 news october 1 2025 trends 2025: real-world data, patient outcomes & future therapies GLP-1 Pipeline Update: November 2025

There's a ton to say about glycine

The program is well underway and will contribute meaningfully to growth in 2023, said Gail Boudreaux, president and CEO of Elevance

During an average follow-up of 26.3 months (2.2 years, SD 1.9 years), the annual rate of acute healthcare utilization was 1.52 visits/year in the GLP1-RA group and 1.67 visits/year within the DPP4i group (coefficient of regression = 0.15, 95% CI 0.25 to 0.05, p = 0.004)

36,37 Findings from other research studies have contradicted this proposition, however, showing that the association between hyperphosphatemia and liver failure is only evident in patients with acute renal failure (with 5080% of patients with acute liver failure having concomitant acute renal failure 38 )

Often called the master antioxidant, it plays a central role in neutralising free radicals, supporting liver detoxification, maintaining immune function, and recycling other antioxidants like vitamins C and E